New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 16, 2022 - The FDA approved Eli Lilly’s Rezvoglar (insulin glargine-aglr), interchangeable biosimilar to Sanofi’s Lantus® (insulin glargine).
Download PDF
Return to publications
